William R Ringo
CIK 1238325 · Chief Executive Officer · last filed 2025-06-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FPRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
TWO TOWER PLACE, 7TH FLOOR
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ASMB | Director | 1,455 | $21.28 | $31.0K | -$510.4K | 23 | 2025-06-09 |
| Sensei Biotherapeutics, Inc. (SNSE) Delisted | Director | 1,170 | $13.85 | $16.2K | $0 | 4 | 2025-05-23 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Chief Executive Officer | 0 | $38.00 | $0 | -$1.78M | 14 | 2021-04-19 |
| DERM | Director | 6,000 | $4.49 | $26.9K | -$165.7K | 17 | 2019-06-14 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Director | 10,000 | $178.75 | $1.79M | -$374.3K | 16 | 2019-06-12 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | 31,800 | $0.18 | $5.6K | -$1.10M | 15 | 2017-09-22 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Director | — | $58.70 | — | $0 | 4 | 2016-05-19 |
| ASSEMBLY BIOSCIENCES, INC. (VTUS) Delisted | Director | 20,465 | — | — | $0 | 1 | 2014-07-14 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Director | 9,837 | — | — | -$400.3K | 7 | 2013-04-01 |
| PFE | Senior Vice President | 255,139 | $29.14 | $7.43M | $0 | 37 | 2010-04-01 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Director | 3,000 | — | — | $0 | 2 | 2007-06-21 |
| INSPIRE PHARMACEUTICALS INC (ISPH) Delisted | Director | — | — | — | $0 | 1 | 2007-06-12 |
Recent Filings · Page 3 of 16
153 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-12-20 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-11-20 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-10-21 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-10-08 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-14 | DERM | Exer (M) | +3,000 | $0 | EDGAR |
| 2019-06-12 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-06 | DERM | Grant (A) | — | $0 | EDGAR |
| 2019-05-17 | ASMB | Grant (A) | — | $0 | EDGAR |
| 2019-04-04 | — | Disp (D) | — | $0 | |
| 2019-01-11 | FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.